ArticleDrug safety2014
Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance.
Article in Drug safety, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Semantic Similarity-Informed Bayesian Borrowing for Quantitative Signal Detection of Adverse Events.Statistics in medicine · 2026Article
- Artificial Intelligence in Pharmacovigilance: Guiding Principles from the CIOMS Working Group XIV.Drug safety · 2026Review
- Critical Appraisal of Artificial Intelligence for Rare-Event Recognition: Principles and Pharmacovigilance Case Studies.Drug safety · 2026Article
- Performance of the Self-Controlled Case Series With Active Comparators for Drug Safety Signal Detection Using the French Administrative Healthcare Database (SNDS).Pharmacoepidemiology and drug safety · 2025Article
- Recommendations to Enable Broader Use of Real-World Evidence to Inform Decision-Making Throughout Pharmacovigilance Signal Management.Pharmacoepidemiology and drug safety · 2025Review
- Artificial intelligence in pharmacovigilance: advancing drug safety monitoring and regulatory integration.Therapeutic advances in drug safety · 2025Review
- Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug-drug interactions.Pharmacoepidemiology and drug safety · 2023Article
- Identifying Safety Subgroups at Risk: Assessing the Agreement Between Statistical Alerting and Patient Subgroup Risk.Drug safety · 2023Article
- Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems.Frontiers in drug safety and regulation · 2023Review
- A reference set of clinically relevant adverse drug-drug interactions.Scientific data · 2022Article
- Augmenting aer2vec: Enriching distributed representations of adverse event report data with orthographic and lexical information.Journal of biomedical informatics · 2021Article
- Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.Drug safety · 2020Article
- Retrofitting Vector Representations of Adverse Event Reporting Data to Structured Knowledge to Improve Pharmacovigilance Signal Detection.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2020Article
- How Confident Are We about Observational Findings in Healthcare: A Benchmark Study.Harvard data science review · 2020Article
- Predicting Adverse Drug-Drug Interactions with Neural Embedding of Semantic PredicationsAMIA ... Annual Symposium proceedings. AMIA Symposium · 2019Article
- Finding missed cases of familial hypercholesterolemia in health systems using machine learning.NPJ digital medicine · 2019Article
- Article
- Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project.Drug safety · 2018Article
- Learning predictive models of drug side-effect relationships from distributed representations of literature-derived semantic predications.Journal of the American Medical Informatics Association : JAMIA · 2018Article
- Improving reproducibility by using high-throughput observational studies with empirical calibration.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2018Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacovigilance seeks to detect and describe adverse drug reactions early. Ideally, we would like to see objective evidence that a chosen signal detection approach can be expected to be effective. The development and evaluation of evidence-based methods require benchmarks for signal detection performance, and recent years have seen unprecedented efforts to build such reference sets. Here, we argue that evaluation should be made against emerging and not established adverse drug reactions, and we present real-world examples that illustrate the relevance of this to pharmacovigilance methods development for both individual case reports and longitudinal health records. The establishment of broader reference sets of emerging safety signals must be made a top priority to achieve more effective pharmacovigilance methods development and evaluation.
Indexed as
Identifiers
25005708What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.